Advertisement Dako, Bristol-Myers in pharmacodiagnostic tests development agreement - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Dako, Bristol-Myers in pharmacodiagnostic tests development agreement

Dako and Bristol-Myers Squibb have entered into a partnership agreement to develop pharmacodiagnostic tests.

The pharmacodiagnostic tests are intended to identify the patients more likely to benefit from treatment with investigational drug candidates under development by Bristol-Myers Squibb.

Dakos CEO Lars Holmkvist said the partnership agreements simply underpin the company’s mission to deliver the highest standards and accurate diagnoses — ultimately to the benefit of patients.